Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Saitama
Clinical trial register · Japan

Clinical Trials in Saitama, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline10 Novo Nordisk A/S6 Hoffmann-La Roche5 Daiichi Sankyo4 BioMarin Pharmaceutical3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Saitama

67 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
GlaxoSmithKline
Phase 3
610
Fukuoka, Fukushima, Hokkaido, Miyagi, Numakunai, Osaka, Saitama, Tokyo
2026-09-24
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Kagoshima, Yokohama, Sakai, Saitama, Chuo-ku, Tachikawa, Toshima-ku
2026-08-24
Recruiting
National Cancer Center, Japan
Phase 2
29
Saitama, Tokyo, Yokohama
2026-08-13
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
Kowa Company, Ltd.
Phase 4
120
Hokkaido, Ibaraki, Kagawa, Kanagawa, Osaka, Saitama, Tokyo
2026-07-01
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Sapporo, Kamimashiki-gun, Kumamoto, Sakai, Saitama, Tokyo
2026-06-15
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Yokohama, Fukuoka, Saitama
2026-04-28
Recruiting
GlaxoSmithKline
Phase 1
97
Saitama, Shizuoka, Tokyo
2026-03-23
Recruiting
Eli Lilly and Company
Phase 3
900
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima
2026-02-09
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Recruiting
Sanofi
Phase 4
35
Kawasaki, Hiroshima, Saitama, Tokyo
2025-09-23
Active, closed
Eli Lilly and Company
Phase 3
800
Fukuoka, Izumo, Kariya, Kawasaki, Minatoku, Miyazaki, Morioka, Saitama
2025-09-15
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Kanazawa, Suita, Fukushima, Okayama, Saitama, Tokyo
2025-06-17
Recruiting
Hoffmann-La Roche
Phase 3
450
Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama
2025-04-09
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Fukuoka, Tsu, Kawagoe, Saitama, Hiroshima, Kawasaki, Nagasaki, Saga
2025-03-20
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Kamakura-shi, Sendai, Kurashiki-shi, Saitama, Fuchu-shi, Fukuoka-ken, Kanagawa, Kawasaki
2025-03-18
Recruiting
Novo Nordisk A/S
Phase 2
465
Koriyama-shi, Fukushima, Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Saitama, Sendai-shi, Miyagi, Siga
2024-12-02
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Kashiwa-shi, Saitama, Tokyo
2024-10-30
Recruiting
GlaxoSmithKline
Phase 3
440
Aichi, Fukuoka, Hiroshima, Hokkaido, Kanagawa, Miyagi, Miyazaki, Saitama
2024-09-11
Active, closed
Gilead Sciences
Phase 3
640
Chiba, Hyōgo, Kanagawa, Mie, Okayama, Saitama, Shizuoka, Tokyo
2024-08-28
Active, closed
GlaxoSmithKline
Phase 3
10,212
Hiroshima, Ibaraki, Kumamoto, Okinawa, Saitama, Shizuoka, Tokyo, Yamagata
2024-08-01
Recruiting
GlaxoSmithKline
Phase 1
675
Saitama, Shizuoka, Tokyo
2024-07-02
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Amagasaki Shi, Kawasaki Shi, Kobe, Kumamoto, Osaka, Ōta-ku, Saitama, Wakayama
2024-04-18
Recruiting
Daiichi Sankyo
Phase 1/2
680
Nagoya, Kashiwa, Matsuyama, Ōsaka-sayama, Nagaizumi-cho, Chuo-ku, Koto-ku, Saitama
2024-04-10
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Hidaka, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi, Saitama
2024-02-26
Active, closed
BioMarin Pharmaceutical
Phase 3
6
Hokkaido, Saitama, Aichi, Tokyo
2023-12-25
Active, closed
GlaxoSmithKline
Phase 2
316
Aichi, Chiba, Hyōgo, Osaka, Saitama, Shizuoka, Tokyo
2023-11-14
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Recruiting
Hoffmann-La Roche
Phase 3
100
Chiba, Fukuoka, Kanagawa, Kashiwa-shi, Saitama, Sakaishi
2023-06-01
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Bunkyō-Ku, Saitama
2023-04-17
Active, closed
Multi-omics Study in Citrin Deficiency
NCT06895746Citrin Deficiency
Johannes Haeberle
Observational
100
Kurume-shi, Saitama, Yokohama, Tokyo, Sendai, Matsumoto, Hokkaido, Osaka
2023-04-01
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Aichi, Gunma, Nara, Saitama, Tochigi, Tokyo
2023-02-13
Active, closed
Sanofi
Phase 2
187
Nagaoka, Hamamatsu, Chūō, Fukushima, Osaka, Ōita, Saitama
2022-11-25
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Sapporo, Suita-shi, Aichi, Chiba-shi, Chiba, Gunma, Kanagawa, Osaka, Saitama
2022-11-01
Active, closed
GlaxoSmithKline
Phase 2
351
Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama
2022-10-14
Active, closed
GlaxoSmithKline
Phase 3
163
Kanagawa, Saitama, Tokyo
2022-07-14
Recruiting
Priothera SAS
Phase 3
366
Anjo-shi, Nagoya, Kanazawa, Osaka, Saitama, Shimotsuke-shi, Fukuoka, Hiroshima
2022-06-16
Active, closed
Heartseed Inc.
Phase 1/2
10
Kawasaki, Saitama, Tokyo
2022-04-19
Active, closed
ARCAGY/ GINECO GROUP
Phase 3
260
Fukuoka, Fukushima, Kōtoku, Saitama
2022-04-15
Active, closed
Novo Nordisk A/S
Phase 3
153
Kanagawa, Saitama
2022-03-24
Active, closed
Hoffmann-La Roche
Phase 3
83
Aichi, Saitama, Tokyo
2021-10-22
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Hokkaido, Kobe, Kumamoto, Kyoto, Nagasaki, Osaka, Saitama, Toyoake
2021-07-06
Active, closed
Savara Inc.
Phase 3
164
Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka
2021-05-19
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Fukuoka, Kanazawa, Kashihara, Kawasaki, Niigata, Okayama, Osaka, Saitama
2020-12-11
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Chiba, Fukuoka, Hokkaido, Hyōgo, Miyagi, Moriguchi, Morioka, Saitama
2020-10-15
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Aichi, Hiroshima, Hyōgo, Niigata, Osaka, Saitama, Shizuoka, Tokyo
2019-11-13
Active, closed
Daiichi Sankyo
Phase 1/2
247
Aichi, Chiba, Hokkaido, Hyōgo, Kagawa, Osaka, Ōsaka-sayama, Saitama
2019-11-03
Active, closed
Novo Nordisk A/S
Phase 3
134
Aichi, Kagoshima, Kanagawa, Mie, Nara, Saitama, Tokyo
2019-10-21
Active, closed
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
DrugsParaplatin·Taxol·Keytruda·Paclitaxel
National Cancer Institute (NCI)
Phase 3
813
Tōon, Kure, Niigata, Saitama
2019-08-22
Active, closed
BioMarin Pharmaceutical
Phase 2
73
Osaka, Saitama, Tokushima
2019-06-12
Recruiting
Insel Gruppe AG, University Hospital Bern
Not applicable
104
Ageo, Gifu, Nagano, Osaka, Saitama, Sapporo
2019-05-28
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Azumino, Kurashiki-shi, Kawagoe-shi, Saitama, Tokyo, Izumi
2019-05-09
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Fukuoka, Hiroshima, Kanagawa, Sagamihara, Saitama, Tokyo, Toyoake
2018-05-14
Active, closed
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Saitama
2018-05-03
Recruiting
Endometrial Cancer Lymphadenectomy Trial
NCT03438474Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
Philipps University Marburg
Not applicable
640
Okayama, Saitama
2018-03-28
Recruiting
Randomization of Single vs Multiple Arterial Grafts
NCT03217006Coronary Artery Disease, Heart Diseases
Weill Medical College of Cornell University
Not applicable
4,300
Saitama
2018-01-07
Active, closed
BioMarin Pharmaceutical
Phase 3
119
Osaka, Saitama, Tokushima
2017-12-12
Active, closed
NRG Oncology
Phase 3
162
Sapporo, Shiwa-gun, Mitaka-shi, Shinjuku-ku, Hiroshima, Saitama, Tokyo
2017-09-12
Recruiting
Italian Sarcoma Group
Not applicable
100
Saitama
2017-03-16
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Tōon, Sapporo, Kagoshima, Koto-ku, Osaka, Saitama, Tokyo
2016-05-03
Active, closed
National Cancer Institute (NCI)
Phase 3
579
Shiwa-gun, Kagoshima, Koto-ku, Saitama, Tokyo
2016-03-28
Active, closed
Hoffmann-La Roche
Phase 3
154
Chiba, Gifu, Saitama
2015-02-02
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Recruiting
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Children's Hospital of Philadelphia
Observational
150,000
Setagaya-Ku, Hiroshima, Kobe, Ōbu, Saitama, Shimotsuke, Tokyo
2010-03
Rows per page Showing 1–67 of 67
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/saitama

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 67 of those studies with a site in Saitama.

How many clinical trials are recruiting in Saitama?

30 of the 67 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 37 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Saitama), 67 studies
PhaseStudiesRecruitingShare
Phase 3351352.2%
Phase 210514.9%
Not applicable7510.4%
Observational416%
Phase 1426%
Phase 1/2314.5%
Phase 4334.5%
Phase 2/3101.5%

Most active sponsors

Lead sponsors with the most studies (Saitama)
Lead sponsorStudiesRecruiting
GlaxoSmithKline106
Novo Nordisk A/S61
Hoffmann-La Roche53
Daiichi Sankyo42
BioMarin Pharmaceutical30
Eli Lilly and Company32
National Cancer Institute (NCI)30
Novartis Pharmaceuticals21
Sanofi21
Weill Medical College of Cornell University22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.